Heidelberg Pharma to Present Promising Clinical Data for Multiple Myeloma Treatment HDP-101
TL;DR
Heidelberg Pharma's HDP-101 shows promising anti-tumor activity, offering a potential competitive advantage in treating relapsed multiple myeloma with novel Amanitin-based ADC technology.
HDP-101 is an anti-BCMA antibody-drug conjugate undergoing Phase I/IIa clinical trials to determine optimal dosing and safety for relapsed or refractory multiple myeloma treatment.
This innovative cancer therapy addresses high unmet medical needs in multiple myeloma patients, potentially improving survival and quality of life for those with limited treatment options.
Heidelberg Pharma pioneers using Amanitin from death cap mushrooms in cancer therapy, presenting breakthrough data at the World ADC Congress and hosting a November 11 webinar.
Heidelberg Pharma AG will present new clinical data from its ongoing Phase I/IIa study evaluating HDP-101, the company's lead Amanitin-based antibody-drug conjugate candidate, at the 16th Annual World ADC Congress in San Diego. The data demonstrate objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the clinical trial for relapsed or refractory multiple myeloma.
HDP-101, with the international nonproprietary name pamlectabart tismanitin, represents a novel therapeutic approach for multiple myeloma, a bone marrow cancer characterized by significant unmet medical needs. The Phase I portion of the study focuses on dose escalation to determine the optimal and safe dosage level in preparation for subsequent Phase II clinical evaluation. The emerging data reinforce both the therapeutic potential and safety profile of this innovative treatment approach.
Professor Andreas Pahl, Chief Executive Officer of Heidelberg Pharma, will present an update from patient cohort 8 including efficacy data during his presentation titled "From Bench to Breakthrough: The Evolution of Amanitin ADCs - Insights from HDP-101 Phase I/II & the Future of Payload Differentiation." The presentation is scheduled for Wednesday, November 5, 2025, at 5:00 pm PST at the Town & Country San Diego venue.
Following the congress, Heidelberg Pharma will host an R&D webinar on November 11, 2025, at 05:00 pm CET for investors, analysts, and media. The webinar will feature presentations by the Heidelberg Pharma management team alongside Key Opinion Leader Professor Marc-Steffen Raab, Head of the Myeloma Center at the University Hospital Heidelberg and clinical investigator of the study. Interested participants can register for the webinar at https://us06web.zoom.us/webinar/register/WN_AG_mESPaT-aSsm8_O2Dll.
The clinical progress of HDP-101 represents significant advancement in ADC technology, particularly as Heidelberg Pharma is the first company to utilize Amanitin from the green death cap mushroom in cancer therapy. This biological mechanism represents a new therapeutic modality used in the company's proprietary ATAC technology platform. The development of HDP-101 addresses the critical need for effective treatments in relapsed or refractory multiple myeloma, where patients often exhaust available therapeutic options.
For additional information about Heidelberg Pharma and its research programs, visit www.heidelberg-pharma.com. The company's approach combines the specificity of antibodies with the efficacy of toxins to create targeted cancer treatments that transport cytotoxic compounds directly into diseased cells, where they unleash their therapeutic effects.
Curated from NewMediaWire